Details for Patent: 6,858,650
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 6,858,650 protect, and when does it expire?
Patent 6,858,650 protects TOVIAZ and is included in one NDA.
Protection for TOVIAZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-eight patent family members in twenty-nine countries.
Summary for Patent: 6,858,650
Title: | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Abstract: | The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyr ate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester. |
Inventor(s): | Meese; Claus (Monheim, DE) |
Assignee: | Schwarz Pharma AG (DE) |
Application Number: | 10/130,214 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,858,650 |
Patent Claim Types: see list of patent claims | Compound; Formulation; Use; |
Drugs Protected by US Patent 6,858,650
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | TOVIAZ | fesoterodine fumarate | TABLET, EXTENDED RELEASE;ORAL | 022030-001 | Oct 31, 2008 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Pfizer | TOVIAZ | fesoterodine fumarate | TABLET, EXTENDED RELEASE;ORAL | 022030-002 | Oct 31, 2008 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,858,650
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Germany | 199 55 190 | Nov 16, 1999 |
PCT Information | |||
PCT Filed | November 15, 2000 | PCT Application Number: | PCT/EP00/11309 |
PCT Publication Date: | May 25, 2001 | PCT Publication Number: | WO01/35957 |
International Family Members for US Patent 6,858,650
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 286872 | See Plans and Pricing | |||
Austria | 337293 | See Plans and Pricing | |||
Austria | 395056 | See Plans and Pricing | |||
Australia | 2666701 | See Plans and Pricing | |||
Australia | 778132 | See Plans and Pricing | |||
Brazil | 0015610 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |